Pfenex Announces Pricing of Follow-On Offering

On April 24, 2015, Pfenex, a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, announced the pricing of its follow-on offering of 6,000,000 shares of its common stock at a price to the public of $15.50 per share. Wilson Sonsini Goodrich & Rosati is advising Pfenex in the offering.

Of the shares being offered, 2,610,000 are being offered by Pfenex, and the remaining 3,390,000 are being offered by existing stockholders. Pfenex will not receive any proceeds from the shares sold by existing stockholders. In addition, Pfenex has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from certain existing stockholders.

The WSGR team advising Pfenex in the offering includes:

Corporate:
Jeff Saper, Partner
Dan Koeppen, Partner
Zach Myers, Associate

Intellectual Property:
Jeff Guise, Partner
Matt Bresnahan, Associate

Technology Transactions:
Ian Edvalson, Partner

For additional information, please see Pfenex's press release.